News & Events

Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in Stage I and II Cohort Study at 2016 AAD Summer Meeting

Boston, MA—July 28, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the results from a study evaluating the performance of its gene expression profile (GEP) test DecisionDx®-Melanoma in a cohort of 356 Stage I and II melanoma patients. The data confirm findings from two previously published multicenter clinical validation studies and further support the test’s a bility to identify patients’ risk of melanoma recurrence in the five years more »

Results of New Study with Castle Biosciences’ Skin Melanoma Gene Expression Test Published in Current Medical Research and Opinion

Friendswood, TX—July 11, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of a prospectively designed, multicenter, decision impact study of its gene expression profile (GEP) test for cutaneous melanoma. The DecisionDx®-Melanoma GEP test accurately predicts etastatic risk independent of current diagnostic modalities including AJCC staging. The paper, “Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients,” was more »

Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in 334-Patient Performance Cohort Study at ASCO 2016

Results confirm accuracy of DecisionDx-Melanoma to identify recurrence risk  A second independent, prospective study confirms test accuracy Chicago, IL—June 6, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the results from a study evaluating the performance of its gene expression profile (GEP) test, DecisionDx®-Melanoma, in 334 new melanoma patients. The data confirmed the positive results from two previously published multicenter clinical validation studies demonstrating the test’s ability to more »

Independent Study Verifies the Performance of Castle Biosciences’ Cutaneous Melanoma Gene Expression Profile Test for Predicting Risk of Metastasis

Friendswood, TX – May 2, 2016 | Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, today announced results of an independent study with its noninvasive gene expression profile test, verifying the accuracy and utility of the assay to identify risk of metastasis in patients diagnosed with Stage I or II cutaneous melanoma. Results were presented in an oral presentation session at the 48th Annual Meeting of the American College of Mohs Surgery in Orlando, FL. The study, titled more »

Melanoma: Amid Caveats, New Test Shown to Improve Prediction of Risk of Metastasis and Survival

Oncology Times | June 30, 2015 | Mark Fuerst | SAN FRANCISCO–A new gene expression profile (GEP) test more accurately predicts the risk of metastasis and survival in patients with cutaneous melanoma compared with the standard predictive method currently used to guide patient management, researchers reported here at the American Academy of Dermatology Annual Meeting. With more testing, they and other experts said, it may allow oncologists to know which patients need early treatment to prevent disease progression. “There is great variability in prognosis in more »

« Newer EntriesOlder Entries »
Know Your Risk

DecisionDx-Melanoma

A new genomic test is designed to predict if your cancer is at high risk of spreading, based on your tumor’s biology. Watch Video
Talk to Your Doctor
Decide with your doctor if DecisionDx-Melanoma is right for you. Download PDF
Gene Test Validation